Stargardt disease is a genetic eye disorder that causes a progressive loss of central vision.
The vision loss is concentrated in the macula, the central area of the retina responsible for high-detail vision for tasks like face recognition or reading. The symptoms are similar to age related macular degeneration, but they are caused by inherited mutation and affect people much earlier in life.



Our Treatment: In clinical trials, PRIMA restored form vision by replacing the function of damaged photoreceptors
Building on decades of pioneering research in miniaturized solar technology, the PRIMA system has two main parts: a small device placed under the retina where the eye's light-sensing cells have been lost; and a pair of glasses that sends both visual data and power in the form of patterned light that is projected on to the implant.
Once implanted, the PRIMA implant uses gentle electrical signals to activate healthy nerve cells in the eye. In our clinical trials, this process enabled some patients to read sequences of letters with a clinically meaningful improvement of letter acuity.
Learn more about PRIMACurrent Status
Science's PRIMAvera clinical study in Europe was focused on AMD and has finished with positive preliminary results. We are currently exploring the possibility of using the PRIMA implant with Stargardt patients.
Patient Registry: Science Corporation is actively seeking people interested in learning more about our vision loss treatments.
Join the Patient Registry
More Resources
More information about treatment options, disease details, and current research